Clinical trials: Metabolism of Clopidogrel
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Healthy Volunteers
An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel
The primary purpose of this study is to assess whether esomeprazole 20 mg/Acetyl Salicylic Acid (ASA) 81 mg affect the metabolism of clopidogrel.
- Trial name
- NCT01210339
- Testing
- Clopidogrel, Esomeprazole/ASA
- Where
- Sweden
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
PTRG-DES Consortium
The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea.
- Conditions
- Coronary Artery Disease, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Stent Thrombosis
- Trial name
- PTRG (NCT04734028)
- Testing
- Clopidogrel Tablets
- Where
- South Korea
- Volunteers
- 13,160 people
- Sponsor
- Gyeongsang National University Hospital
Diabetes Mellitus, Type 2
PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor
The purpose of this study is to determine whether Ticagrelor has a protective effect on microcirculation during percutaneous coronary interventions in patients with Diabetes mellitus type II or in a pre-diabetic status.
- Trial name
- PREDICT (NCT02698618)
- Testing
- Diagnostic, Randomization, PCI
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Diabetes Mellitus, Type 2, Coronary Artery Disease
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm.
- Trial name
- OPTIMUS-7 (NCT04484259)
- Testing
- Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Florida
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Ischemic Stroke, Peripheral Artery Disease
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
Investigation of the clinical efficacy and safety of dual antiplatelet therapy with clopidogrel and cilostazol versus clopidogrel alone in preventing ischemic vascular events in patients with type 2 diabetes and symptomatic…
- Conditions
- Ischemic Stroke, Peripheral Artery Disease, Diabetes Mellitus, Type 2
- Trial name
- DORIC (NCT02983214)
- Testing
- Clopidogrel, Cilostazol
- Where
- Greece
- Volunteers
- 826 people
- Sponsor
- University of Ioannina
Hypercholesterolemia, Thrombosis
The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A
The objective of this study is to determine if the action of the drug called clopidogrel, that you will start taking, will be decreased by another drug called atorvastatin, that you will also start taking.
- Trial name
- NCT00004564
- Testing
- Clopidogrel, Atorvastatin
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Metabolism of Clopidogrel
Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug.
- Trial name
- PGXB2B (NCT01341600)
- Testing
- Clopidogrel, Omeprazole/Clopidogrel
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
G6PD Deficiency, Stroke
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency on some occasions, while still widely uesd for stroke prevention.
- Trial name
- SAST (NCT04088513)
- Testing
- Aspirin, Clopidogrel
- Where
- 19 sites in China
- Volunteers
- 440 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Diabetes Mellitus Type II, Acute Coronary Syndrome
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
The purpose of this study is to determine if, in type 2 diabetic patients undergoing treatment with PCI and a stent, who fail to respond to normal doses of clopidogrel, a loading dose of 60 mg of prasugrel followed by 10 mg once…
- Trial name
- VERDI (NCT01684813)
- Testing
- Prasugrel., Clopidogrel
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Type-2 Diabetes Mellitus, Coronary Artery Disease
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes.
- Trial name
- NCT01823510
- Testing
- Ticagrelor + Aspirin, Clopidogrel + Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Juan J Badimon
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Diabetes Mellitus, Coronary Artery Disease
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers.
- Trial name
- OPTIMUS-3 (NCT00642174)
- Testing
- prasugrel, Clopidogrel
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease, Diabetes Mellitus
Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk
Ramadan fasting (RF) has been shown to be associated with vascular and metabolic disorders including glycemic control and lipid profile. It may also alter pharmacologic properties of some medications.
- Trial name
- RFeCloR (NCT02624583)
- Where
- 2 sites in Tunisia
- Volunteers
- 98 people
- Sponsor
- University of Monastir
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
Coronary Artery Disease, Atherosclerosis
Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)
The risk of thrombotic complications after implantation of drug-eluting stents (DES) may be increased in patients with diabetes mellitus (DM) or metabolic syndrome (MS).
- Conditions
- Coronary Artery Disease, Atherosclerosis, Diabetes Mellitus, Metabolic Syndrome X
- Trial name
- SPACE (NCT00298428)
- Testing
- blood samples
- Where
- 2 sites in France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
- Conditions
- Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease
- Trial name
- NCT04007055
- Testing
- Point of care screening for HPR, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Marissa Jarosinski
Type 2 Diabetes Mellitus, Coronary Artery Disease
Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)
Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are…
- Trial name
- NCT00728156
- Testing
- clopidogrel
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust